Patrick Lindsay, UBC’s President and CEO, said, “We are excited by the compelling opportunities this acquisition presents to expand the industry’s leading one-stop-shop for full-service REMS programs. The combination of Examoto’s technology-driven approach with UBC’s scientific, technological, and operational expertise will ensure the most efficient delivery of successful REMS programs to patients and clients.”
“Examoto’s technology and design innovations, in concert with UBC’s Project Management Office and related REMS services, creates a REMS powerhouse. We will collectively have the most comprehensive, proven capabilities for risk mitigation solutions for the pharma industry,” concluded Jason Leedy, Examoto’s Founder. “This strategic combination will encourage efficiency, quality, creativity, and synergy across the various REMS workflows and will provide sponsors with a single point of responsibility for their clinical programs.”
Natalie O’Donnell, Corporate Vice President, UBC Safety and Risk Management, added, “Today’s healthcare market increasingly demands evidence of drug safety and effectiveness to ensure sufficient validation. Our acquisition of Examoto helps cement UBC’s status as a preeminent leader in this category with a full-service REMS solution that leverages enhanced technologies and product innovations to help mitigate safety risk while optimizing the commercialization and delivery of products to market.”
United BioSource LLC (UBC) is a leader in the biopharmaceutical market that provides integrated clinical, safety, and commercialization services. UBC combines renowned scientific research and operations experts with innovative technologies, allowing for the best patient and healthcare provider experience. Comprehensive, end-to-end services cover product and patient population characterization during development and market entry, as well as a focus on the patient experience, safety, and adherence. For additional information, visit www.ubc.com.
About Examoto, LLC
Examoto, LLC is a leader in FDA-mandated REMS compliance platforms addressing safer pharmaceutical outcomes. Built on decades of expertise, Examoto addresses the goals of maximizing the benefits and safe use of prescription drugs while reducing the burden to patients, healthcare providers, and the healthcare delivery system. Examoto accomplishes this through the design, development, deployment, and streamlined operation of technologically driven REMS services including web, mobile, data, voice, SMS, and chat for public digital environments. For more information, visit www.examoto.com.
SOURCE United BioSource Corporation